PROCAINE amide was introduced for the treatment of cardiac arrhythmias 6 years ago. Since then a number of studies with the compound have been reported. A review of the results may help in appraising the value of the drug as a therapeutic agent.
The first step toward the development of procaine amide was taken when Mautz,' in 1936, showed that procaine, applied directly to the myocardium of animals, elevated the threshold of ventricular muscle to electric stimulation. Beck and Mautz2 then demonstrated that the topical application of procaine in surgery involving stripping of the pericardium, reduced the occurrence of ventricular and atrial extrasystoles. In 1946, Burstein3 reported that procaine was an effective antiarrhythmic agent when injected intravenously, and he employed it in anesthetized patients prophylactically as well as therapeutically. Although of undoubted effective antiarrhythmic activity, procaine has limited use in the general treatment of arrhythmias because of its central stimulatory effects, which restrict its use to anesthetized patients.
A study on the fate of procaine in man showed that the drug after intravenous injection was enzymatically hydrolysed in plasma with extreme rapidity to para-aminobenzoic acid and diethylaminoethanol. 4 The rapid hydrolysis of procaine suggested that its antiarrhythmic action might be mediated through one of the metabolites. Para-aminobenzoic acid was found to activity but diethylaminoethanol in large dosage protected dogs against arrhythmias induced by cyclopropane and epinephrine and was effective in patients with ventricular tachycardia.5 A number of other dialkylamino alcohols closely related in structure to diethylaminoethanol were shown to be ineffective as antiarrhythmic agents in nontoxic doses.6
Although diethylaminoethanol had undoubted antiarrhythmic action, the large doses required in man indicated that the action of procaine was not mediated through this metabolite, and the hypotension resulting from its use made the compound undesirable as a therapeutic agent. The striking observation, however, that the compound was effective in doses that had minimal central stimulatory effects stimulated a search for a drug having the potency of procaine but lacking its central stimulatory action. A number of derivatives of diethylaminoethanol were synthesized. * The compounds were screened in dogs for their efficacy in protecting against ventricular tachycardia induced by cyclopropane and epinephrine. The most potent compound among these studied was There have been several experimental studies on the effects of procaine amide in digitalis-intoxicated animals.'8-20 Goldberg and Cottenl8 produced ventricular tachycardia in 14 dogs with digitoxin or ouabain and reverted 8 of the animals to normal sinus rhythm with intravenous procaine amide. In the 6 other animals, procaine amide produced slow idioventricular rhythms, followed in 4 animals by cardiac arrest. These authors also reported that procaine amide did not, increase the lethal dose of ouabain in cats. AMosey and Tyleir19
found that procaine amide reverted the xentricular tachycardia produced with ouabain in 7 of 8 dogs.
Zapata Diaz, and co-workers2" also stressed the fact that procaine amide might eliminate ventricular extrasystoles and ventricular tachycardia caused by digitalis. Their work also indicated that the drug might also initiate ventricular fibrillation since, in their dogs, procaine amide increased the delay in intraventricular conduction originally caused by digitalis. These additional toxic effects occurred only after doses of procaine amide (150-325 mg./Kg.) considerably higher than the therapeutic doses used in man.
The ganglionic-blocking properties of procaine amide were studied by Paton and Thompson2l in the superior cervical ganglion of the cat. Their observations indicated that procaine amide not only antagonizes the effects of acetylcholine, but inhibits its release at the ganglion.
The actions of procaine amide on the central nervous system are not prominent, but a large dose rapidly injected in dogs will cause tremors.8 Procaine amide has local anesthetic activity comparable to procaine, but it is not very effective for blockade of nerve trunks.'0 Man. Studies of the electrocardiographic effects have shown prolongation of the P-R, QRS, and Q-T intervals, indicating a delayed rate of conduction in atrium and A-V node, a delay in intraventricular conduction, and a prolongation of the refractory period. The clinical reports on the use of procaine amide in patients who have developed rhythmic disturbances due to excessive dosage with digitalis are not in entire agreement.23-30 In our experience, it has been a useful agent in correcting these abnormalities, although 1 patient who received only 145 mg. of procaine amide intravenously directly after an intravenous dose of lanatoside-C developed ventricular fibrillation, possibly due to the procaine amide. Other groups also recommend using procaine amide as a therapeutic agent in the treatment of arrhythmias caused by excessive digitalis dosage.2730 However, in view of the experimental work of Zapata's group procaine amide should probably be used cautiously when a digitalis compound has been administered.
EFFECTS ON VARIous ARRHYTHMIAS IN MAN
In reviewing reports on the efficacy of procaine amide in the various arrhythmias,31-68 it was noted that some authors described results in terms of success, partial success, and failure, while others recorded only success and failure. Partial success, in some cases, referred only to slowing of the aberrant rhythm without reestablishment of the normal, in other cases to incomplete abolition of ectopic foci, and in still others to a temporary correction of the abnormal rhythms. In calculating per cent success for table 1, partial success has been regarded as failure. A variety of dosage schedules have been employed in treating cardiac arrhythmias. When procaine amide is administered intravenously, the rate of injection appears to be as important as the total dose. The use of electrocardiographic control and frequent recordings of blood pressure are essential for safety when procaine amide is given intravenously, but whets administered slowly (50-75 mg.,/'miss.), as much as 3 Gm. has been given38 without uitoward effects. It is well to stress that in the absence of hypotension and electrocardiographic abisormalities produced by the drug, it may be given until the desired effect is achieved, but intravenous administ ratiots enstails certain dangers because of sudden development of cardiac abnormalities. The intramuscular route provides greater safety and single doses of 0.5 to 1 Gm. at repeated intervals have been satisfactory.58 The intravetsous route should be reserved for those patients whose desperate cotsditioss requires immediate therapy.
The oral dose of procaine amide required to revert any particular arrhythmia is variable. An initial dose of 1 Gm. followed by 0.t5f to 1 Gm. doses every 3 to 4 hours is adequate for many patients, but the total daily dose may reach 10 Gm. to revert, ais arrhythmia or provide prophylaxis against recurrences. The usual effective dose is about 3 to 6 Gim./day, but if the desired effect has not been achieved after 48 hours, the dose should be increased, either by increasing the frequency or increasing the individual dose, since a stable plasma level is reached after 24 to 48 hours. Toxic effects, such as nausea and gastrointestinal irritation on1 5 Gm. a day may occasionally be so pronounced as to prevent, further administration, but many patients take this dose without any difficulty.59 TOXICITY Early reports oIt procaine amide indicated that toxic reactions occurred involving the circulatory, gastrointestinal, and central nervous system. Subsequent reports have included these and a number of other complications. The electrocardiogram is frequently altered, but the prolongation in the P-It, QRS, or Q-T intervals need not necessarily be regarded as toxic manifestations, but rather as manifestations of effects ott cardiac muscle essential to the action of the drug. However, toxicity can occur due to excessive effects on conductivity and refractory period. As conductivity and refractory period are prolonged, the depressant action on ectopic foci may be inadequate and ventricular extrasystoles, ventricular tachycardia, and even ventricular fibrillation may occur.60-64 This may be due to local changes (excitability versus depression) in areas of ventricular muscle and the establishment of dominance by 1 focus. In some cases, the apparent induced ventricular arrhythmia is more likely due to aberrant conduction through the ventricular muscle from the supravenitricular pacemaker, but electrocardiographic differenstiation is frequently impossible in the absence of esophageal recording. During treatment of 7 cases of atrial flutter and 1 of atrial tachycardia, the development of rapid ventricular response to supraventricular pacemaker (1:1 response) was noted. The occurrence of cardiac standstill has been reported,61568 and this is a hazard in the treatmetst of ventricular tachycardia. The depressant, effects of procaine amide may be as marked ots the basic pacemaker of the heart as ott the ectopic focus, and cardiac standstill mnay follow the cessation of abisormal rhythms.
There Quinidine has had extensive use for the past 30 years and it will be many years before an equivalent experience can be gained with procaine amide. Many reports have stressed that the particular arrhythmia being treated was refractory to therapy with quinidine but subsequently responded to procaine amide. The reverse has also been reported, particularly in the management of supraventricular arrhythmias, and there are some instances in which both are effective. Some writers have suggested that a mathematic relationship exists between the effective dose of quinidine and of procaine amide, in the ratio of 1:3 or 1: 4.78 While this may be true in the maintenance dose of a particular patient, there is a wide range of dosage response of both drugs in the many arrhythmias studied and failure to respond to very large doses of quinidine does not mean that a large amount of procaine amide will be required for reversion, and vice versa. The pharmacologic and physiologic studies have shown similar qualitative effects but the quantitative differences that exist may explain differences in effectiveness of these 2 drugs. It appears that it is safer to give procaine amide than quinidine intravenously. When it is obligatory to use this route of administration, procaine amide may well be the first choice. MAJOR 
USES
Articles published during these 6 years suggest that procaine amide is an effective antiarrhythmic agent whose major uses appear at present to be as follows: 1. For the management of ventricular premature contractions whether due to intrinsic heart disease, digitalis toxicity, or unknown cause. 2. In the management of ventricular tachycardia, particularly when it is desired to use an intravenous agent.
3. For the treatment of nodal arrhythmias and recent atrial arrhythmias. 4 . During the course of myocardial infarction as a prophylaxis against ventricular tachycardia and fibrillation, once ventricular premature contractions are observed. The authors do not recommend its use routinely as a prophylactic agent in surgery or cardiac catheterization, since the drug does not appear to exert much control over extrasystoles due to mechanical stimuli.
That this compound was found, suggests that other compounds with these pharmacologic properties exist, some perhaps even more potent and less toxic than procaine amide. Certainly, a further search is warranted.
